The Molecular Profiling to Predict Response to Treatment (MP2PRT) initiative will implement the Blue-Ribbon Panel?s recommendation by leveraging biospecimens collected from completed trials (with available outcome results) that were conducted by the NCI National Clinical Trials Network (NCTN) Program and/or the NCI Community Oncology Research Program (NCORP) and stored in their associated biospecimen repositories. Appropriate research projects solicited from the NCTN/NCORP Groups with archived biospecimens will be selected for molecular characterization under an NCI-designated, multidisciplinary review process with support from this Task Order. The Task Order will support an integrated approach to the molecular characterization of the archived biospecimens (e.g., tumor tissue/normal tissue, whole blood, plasma, serum) from the selected NCTN or NCORP trials, the comprehensive analysis of the molecular characterization data with trial outcome data including predictive and prognostic modeling, and the provision of data sharing of results by depositing the results in the NCI Genomic Data Commons (as well as having the appropriate NCTN/NCORP Group deposit the clinical trial data in the NCTN/NCORP Data Archive, if appropriate).
